Growing questions over exclusive reimbursement contracts – and whether or not they are fair play when it comes to defending entrenched brands – are poised to be decided in court. The second lawsuit in just over a week charging anti-competitive practices related to exclusive contracting by drug makers was filed Oct. 2 in New Jersey district court by Shire PLC.
Shire alleges that Allergan PLC has coerced payers under Medicare Part D to exclude its new dry eye disease...







